BeOne Medicines (BEIGF) Cash & Current Investments (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Cash & Current Investments data on file, last reported at $4.8 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $4.8 billion, up 90.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 90.42% YoY), and the FY2025 annual result was $4.5 billion, up 73.08% from the prior year.
• Cash & Current Investments advanced to $4.8 billion in Q1 2026 per BEIGF's latest filing, from $4.5 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $5.7 billion in Q2 2022 and troughed at $872.2 million in Q3 2022.
• A 5-year average of $3.3 billion and a median of $3.2 billion in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments tumbled 77.73% in 2022, then surged 263.95% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $4.5 billion in 2022, then retreated by 30.0% to $3.2 billion in 2023, then declined by 17.23% to $2.6 billion in 2024, then jumped by 73.08% to $4.5 billion in 2025, then advanced by 5.37% to $4.8 billion in 2026.
• Business Quant data shows BEIGF's Cash & Current Investments at $4.8 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.